Will the new Alzheimer’s drug put pressure on Medicare premiums?
The FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the
Read More
Part D/Prescription Drugs
10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year
(By Chris Lee for The Kaiser Family Foundation published July 12, 2023) A new KFF analysis finds that the 10
Read MoreWait, What’s a PBM?
(By Dan Weissmann for KFF Health News) You might wonder, wait, what’s a PBM exactly? And also, why am I
Read MoreHHS Announces Actions to Protect Consumers and Lower Health Care Costs
(Source – www.cms.gov/newsroom) The U.S. Department of Health and Human Services (HHS), announced actions to protect consumers from junk health
Read MoreLeqembi could cost Medicare up to $17.8B
(By Rylee Wilson for Becker’s Hospital Review) Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease, will
Read MoreStatement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval
(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following
Read MoreWhat to know about the drug price fight in those TV ads
(By Arthur Allen for NPR) In recent months ominous ads about prescription drugs have flooded the TV airwaves. Perhaps by
Read MoreCMS Releases Revised Guidance for Historic Medicare Drug Price Negotiation Program
(Source – www.cms.gov/newsroom) For the first time in history, Medicare has the ability to directly negotiate the prices of covered
Read MoreWhy the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
(By Arthur Allen for KFF Health News) This week the FDA is expected to approve what many scientists and doctors
Read MorePatients Squeezed in Fight Over Who Gets to Bill for Pricey Infusion Drugs
(By Samantha Liss for KFF Health News) Health insurers and medical providers are battling over who should supply high-cost infusion
Read More